Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

This study is testing a combination treatment for newly diagnosed mantle cell lymphoma (MCL) — a type of blood cancer — using two drugs (orelabrutinib and rituximab), with the option of a stem cell transplant for eligible patients. The goal is to evaluate how well this combination controls the cancer. **You may be eligible if...** - You are over 14 years old with a confirmed diagnosis of mantle cell lymphoma - You have not previously received treatment for this cancer - You have measurable disease in at least one location - Your blood counts and liver and kidney function meet the required thresholds **You may NOT be eligible if...** - You have already received treatment for mantle cell lymphoma - Your blood counts, liver function, or kidney function are below acceptable levels - You have serious cardiovascular or other health conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.